CA3140170A1 - Imidazolo derivatives, compositions and methods as orexin antagonists - Google Patents

Imidazolo derivatives, compositions and methods as orexin antagonists Download PDF

Info

Publication number
CA3140170A1
CA3140170A1 CA3140170A CA3140170A CA3140170A1 CA 3140170 A1 CA3140170 A1 CA 3140170A1 CA 3140170 A CA3140170 A CA 3140170A CA 3140170 A CA3140170 A CA 3140170A CA 3140170 A1 CA3140170 A1 CA 3140170A1
Authority
CA
Canada
Prior art keywords
group
substituted
alkyl
halogen
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3140170A
Other languages
English (en)
French (fr)
Inventor
Belew Mekonnen
Hemantbhai Patel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hager Biosciences LLC
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA3140170A1 publication Critical patent/CA3140170A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CA3140170A 2019-06-04 2020-06-03 Imidazolo derivatives, compositions and methods as orexin antagonists Pending CA3140170A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962856830P 2019-06-04 2019-06-04
US62/856,830 2019-06-04
PCT/US2020/035848 WO2020247445A1 (en) 2019-06-04 2020-06-03 Imidazolo derivatives, compositions and methods as orexin antagonists

Publications (1)

Publication Number Publication Date
CA3140170A1 true CA3140170A1 (en) 2020-12-10

Family

ID=73652477

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3140170A Pending CA3140170A1 (en) 2019-06-04 2020-06-03 Imidazolo derivatives, compositions and methods as orexin antagonists

Country Status (9)

Country Link
US (2) US12187737B2 (https=)
EP (1) EP3972588A4 (https=)
JP (1) JP2022534704A (https=)
KR (1) KR20220016918A (https=)
CN (1) CN114286675A (https=)
AU (1) AU2020286381C1 (https=)
CA (1) CA3140170A1 (https=)
SG (1) SG11202112827QA (https=)
WO (1) WO2020247445A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020286381C1 (en) 2019-06-04 2025-07-10 Hager Biosciences, Llc Imidazolo derivatives, compositions and methods as orexin antagonists
AU2020288559C1 (en) * 2019-06-04 2025-07-24 Hager Biosciences, Llc Pyrazole and imidazole derivatives, compositions and methods as orexin antagonists
MX2022007376A (es) 2019-12-20 2022-09-02 Tenaya Therapeutics Inc Fluoroalqull-oxadiazoles y sus usos.
US20240252502A1 (en) 2021-05-04 2024-08-01 Tenaya Therapeutics, Inc. Hdac6 inhibitors for treatment of metabolic disease and hfpef
GB202311281D0 (en) 2023-07-21 2023-09-06 Bial Portela & Ca Sa Orexin receptor antagonists
GB202311280D0 (en) 2023-07-21 2023-09-06 Bial Portela & Ca Sa Orexin receptor antagonists
WO2025101004A1 (ko) * 2023-11-08 2025-05-15 한양대학교 에리카산학협력단 6-aryl imidazo[2,1-b]thi/oxazole-2-carboxilic acid 유도체 및 이를 유효성분으로 함유하는 알츠하이머병 치료용 약학 조성물
WO2025188753A1 (en) * 2024-03-05 2025-09-12 Hager Biosciences, Llc Pyrazole and imidazole derivatives as dual orexin and kappa-opioid receptors modulators, compositions, and methods for treating neurological and psychiatric disorders

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02237988A (ja) 1988-11-18 1990-09-20 Nissan Chem Ind Ltd イソオキサゾロピリジン系メバロノラクトン類
US5750542A (en) 1993-09-28 1998-05-12 Pfizer Benzisoxazole and benzisothizole derivatives as cholinesterase inhibitors
JP3810097B2 (ja) 1993-01-15 2006-08-16 明治製菓株式会社 ピロリジン−２−イルカルボニル複素環式化合物誘導体
US6372757B1 (en) 1998-05-08 2002-04-16 Smithkline Beecham P.L.C. Phenylurea and phenylthio urea derivatives
TR200101754T2 (tr) 1998-12-18 2002-05-21 Schering Corporation Farnezil protein transferaz inhibitörleri
GB0004297D0 (en) 2000-02-23 2000-04-12 Ucb Sa 2-oxo-1 pyrrolidine derivatives process for preparing them and their uses
ES2238458T3 (es) 2000-06-16 2005-09-01 Smithkline Beecham Plc Piperidinas para uso como antagonistas de los receptores de orexina.
WO2002044172A1 (en) 2000-11-28 2002-06-06 Smithkline Beecham P.L.C. Morpholine derivatives as antagonists of orexin receptors
WO2002090355A1 (en) 2001-05-05 2002-11-14 Smithkline Beecham P.L.C. N-aroyl cyclic amines
GB0115862D0 (en) * 2001-06-28 2001-08-22 Smithkline Beecham Plc Compounds
GB0130393D0 (en) 2001-12-19 2002-02-06 Smithkline Beecham Plc Compounds
US7057042B2 (en) 2002-05-29 2006-06-06 Abbott Laboratories Fused bicyclic aromatic compounds that are useful in treating sexual dysfunction
DE60309481T2 (de) 2002-09-18 2007-06-21 Glaxo Group Ltd., Greenford Cyclische n-aroylamine als orexinrezeptorantagonisten
US20080119515A1 (en) * 2003-03-10 2008-05-22 M Arshad Siddiqui Heterocyclic Kinase Inhibitors: Methods of Use and Synthesis
UA85937C2 (uk) 2004-12-21 2009-03-10 Пфайзер Продактс Інк. Макроліди
DE102005016547A1 (de) 2005-04-08 2006-10-12 Grünenthal GmbH Substituierte 5,6,7,8-Tetrahydro-imidazo(1,2-a)pyridin-2-ylamin-Verbindungen und deren Verwendung zur Herstellung von Arzneimitteln
WO2006127550A1 (en) 2005-05-23 2006-11-30 Merck & Co., Inc. Proline bis-amide orexin receptor antagonists
PE20081229A1 (es) 2006-12-01 2008-08-28 Merck & Co Inc Antagonistas de receptor de orexina de diazepam sustituido
CN101627028B (zh) * 2006-12-01 2013-03-27 默沙东公司 作为食欲素受体拮抗剂的取代的二氮杂环庚烷化合物
NZ580887A (en) 2007-05-23 2012-03-30 Merck Sharp & Dohme Pyridyl piperidine orexin receptor antagonists
ES2371514T3 (es) 2007-07-03 2012-01-04 Actelion Pharmaceuticals Ltd. Compuestos de 3-aza-biciclo[3.3.0]octano.
US8263591B2 (en) 2007-08-10 2012-09-11 Cortex Pharmaceuticals, Inc. Bicyclic amides for enhancing glutamatergic synaptic responses
FR2925907B1 (fr) 2008-01-02 2010-10-15 Sanofi Aventis DERIVES DE 2-HETEROAROYL-IMIDAZO°1,2-a!PYRIDINE, LEUR PREPARATION ET LEUR APPLICATION EN THERAPEUTIQUE
JP5346043B2 (ja) 2008-02-12 2013-11-20 エフ．ホフマン−ラ ロシュ アーゲー ピペリジンスルホンアミド誘導体
US8710076B2 (en) 2008-10-21 2014-04-29 Merck Sharp & Dohme Corp. 2,5-disubstituted piperidine orexin receptor antagonists
JP2012506374A (ja) 2008-10-21 2012-03-15 メルク・シャープ・エンド・ドーム・コーポレイション ２，５−二置換ピペリジンオレキシン受容体アンタゴニスト
WO2010048016A1 (en) 2008-10-21 2010-04-29 Merck Sharp & Dohme Corp. 2,3-disubstituted piperidine orexin receptor antagonists
EP2438041A4 (en) 2009-06-01 2012-11-21 Merck Sharp & Dohme PYRAZINE-carboxamide-orexin receptor Antagonist
WO2011005636A1 (en) 2009-07-09 2011-01-13 Merck Sharp & Dohme Corp. Tetrahydronapthyridine orexin receptor antagonists
MX2012009377A (es) 2010-02-11 2012-09-12 Univ Vanderbilt Benzotiazoles y azabenzotiazoles como potenciadores alostericos mglur4, composiciones y metodos para tratar la disfuncion neurologica.
US8614242B2 (en) * 2010-10-21 2013-12-24 Bayer Intellectual Property Gmbh 1-(heterocyclic carbonyl)-2-substituted pyrrolidines
US20120165339A1 (en) 2010-12-22 2012-06-28 Eisai R&D Management Co., Ltd. Cyclopropane derivatives
CA2823877C (en) * 2011-02-18 2020-01-07 Idorsia Pharmaceuticals Ltd Novel pyrazole and imidazole derivatives useful as orexin antagonists
US20140228377A1 (en) 2011-07-05 2014-08-14 Taisho Pharmaceutical Co., Ltd. Methylpiperidine derivative
EP2771346A4 (en) 2011-10-25 2015-06-03 Merck Sharp & Dohme ISOXAZOLOPYRIDIN-orexin
CA2863413A1 (en) 2012-02-07 2013-08-15 Eolas Therapeutics, Inc. Substituted prolines / piperidines as orexin receptor antagonists
TW201444849A (zh) 2013-03-13 2014-12-01 Janssen Pharmaceutica Nv 經取代的7-氮雜雙環類及其作為食慾激素受體調節劑之用途
NZ760341A (en) 2013-12-20 2021-12-24 Agenebio Inc Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
US10081624B2 (en) * 2014-08-26 2018-09-25 Takeda Pharmaceutical Company Limited Heterocyclic compound
AU2020286381C1 (en) 2019-06-04 2025-07-10 Hager Biosciences, Llc Imidazolo derivatives, compositions and methods as orexin antagonists
AU2020288559C1 (en) * 2019-06-04 2025-07-24 Hager Biosciences, Llc Pyrazole and imidazole derivatives, compositions and methods as orexin antagonists

Also Published As

Publication number Publication date
AU2020286381A1 (en) 2022-01-20
WO2020247445A1 (en) 2020-12-10
US12187738B2 (en) 2025-01-07
AU2020286381C1 (en) 2025-07-10
CN114286675A (zh) 2022-04-05
KR20220016918A (ko) 2022-02-10
US12187737B2 (en) 2025-01-07
US20240409554A1 (en) 2024-12-12
SG11202112827QA (en) 2021-12-30
US20220259224A1 (en) 2022-08-18
EP3972588A1 (en) 2022-03-30
EP3972588A4 (en) 2023-05-31
AU2020286381B2 (en) 2025-04-03
JP2022534704A (ja) 2022-08-03

Similar Documents

Publication Publication Date Title
US12187738B2 (en) Imidazolo derivatives, compositions and methods as orexin antagonists
US12275744B2 (en) Pyrazole and imidazole derivatives, compositions and methods as orexin antagonists
AU2013327505B2 (en) Anti-fibrotic pyridinones
CA3129067A1 (en) Thioeno[3,2-b] pyridin-7-amine compounds for treating familial dysautonomia
TW201823208A (zh) N－醯基胺基酸化合物及其使用方法
BR112018002304B1 (pt) Compostos de derivado de 1,3,4-oxadiazol como inibidor de histona desacetilase 6 e a composição farmacêutica que compreende os mesmos
CA3018346A1 (en) 6-hydroxy-4-oxo-1,4-dihydropyrimidine-5-carboxamides as apj agonists
EP3821947A1 (en) Heterocyclic trpml1 agonists
EP3102573A1 (en) Substituted thiazole or oxazole p2x7 receptor antagonists
AU2023329899A1 (en) Substituted pyrazoles and imidazoles as orexin receptor antagonists composition, methods for treating neurological and psychiatric disorders
WO2025188753A1 (en) Pyrazole and imidazole derivatives as dual orexin and kappa-opioid receptors modulators, compositions, and methods for treating neurological and psychiatric disorders
US20260070922A1 (en) Pyrazole and imidazole derivatives as dual orexin and kappa-opioid receptors modulators composition, methods for treating neurological and psychiatric disorders
TW202115023A (zh) 新型細胞凋亡訊號調節激酶1抑制劑
HK40028252A (en) Halo-allylamine ssao/vap-1 inhibitor and use thereof
NZ786241A (en) 6-hydroxy-4-oxo-1,4-dihydropyrimidine-5-carboxamides as apj agonists

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20240527

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20250606

B12 Application deemed to be withdrawn, abandoned or lapsed

Free format text: ST27 STATUS EVENT CODE: N-6-6-B10-B12-B303 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO AN EXAMINER'S REQUISITION

Effective date: 20251006

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251118

U13 Renewal or maintenance fee not paid

Free format text: ST27 STATUS EVENT CODE: N-2-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE

Effective date: 20260119